Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease

Pediatric Infectious Disease Journal

Volumn 17, Issue 6, 1998, Pages 447-452

  Bass, James W ^a   Freitas, Bonnie Cary ^a   Freitas, Alexander D ^a   Sisler, Cheryl L ^a   Chan, Debora S ^a   Vincent, Judy M ^a   Person, Donald A ^a   Claybaugh, John R ^a   Wittler, Robert R ^b   Weisse, Martin E ^c   Regnery, Russell L ^d   Slater, Leonard N ^e  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Azithromycin; Bartonella henselae; Cat scratch disease

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ARTICLE; BARTONELLA HENSELAE; CAT SCRATCH DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; ECHOGRAPHY; FEMALE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BARTONELLA HENSELAE; CAT-SCRATCH DISEASE; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031806264     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199806000-00002     Document Type: Article

References (13)

1. Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997;16:193-79.
2. Anderson BE, Neuman MA. Bartonella spp. as emerging human pathogens. Clin Microbiol Rev 1997;10:203-19.
3. Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992;11:474-8.
4. Demers DM, Bass JW, Vincent JM, et al. Cat-scratch disease in Hawaii: etiology and seroepidemiology. J Pediatr 1995;127: 23-6.
5. Maurin M, Raoult D. Antimicrobial susceptibility of Rochalimaea quintana, Rochalimaea vinsoni, and the newly recognized Rochalimaea henselae. J Antimicrob Chemothr 1993; 32:587-94.
6. Pickett DA, Welch DF. Susceptibility testing of Bartonella spp [Abstract C102]. Presented at the 95th General Meeting, American Society of Microbiology, Session 37, Washington, DC, May, 1995.
7. Gladue RP, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62.993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
8. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
9. Nahata MC. Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis. Pediatr Infect Dis J 1995;14:S39-44.
10. Marshall G, Oyen R, Verschakelen J, Gelin J, Baert AL, Stressens RC. Sonographic appearance of normal lymph nodes. J Ultrasound Med 1985;4:417-9.
11. Young WW, Ahuja A, Tanf A, et al. Ultrasonographic demonstration of normal axillary lymph nodes: a learning curve. J Ultrasound Med 1995;14:823-7.
12. Regnery RL, Olson JG, Bradley AP, Bibb W. Serological response to "Rochalimaea henselae" antigen in suspected cat-scratch disease. Lancet 1992;339:1443-5.
13. Welch DF, Hensel DM, Pickett DA, San Joaquin VH, Robinson A, Slater LN. Bacteremia in a child due to Rochalimaea henselae: practical identification of isolates in the clinical laboratory. J Clin Microbiol 1993;31:2381-6.